CYTK
Cytokinetics, Incorporated
NASDAQ · Healthcare · Biotechnology · US
$72.72
−1.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 71.0M | 88.0M | 18.5M | 7.5M | 94.6M |
| Cost of Revenue | 10.7M | 10.1M | 339.4M | 330.1M | 240.8M |
| Gross Profit | 60.3M | 77.9M | (320.9M) | (322.6M) | (146.2M) |
| Operating Expenses | |||||
| R&D Expense | 394.1M | 405.9M | 339.4M | 330.1M | 240.8M |
| SG&A Expense | 370.5M | 284.3M | 215.3M | 173.6M | 178.0M |
| General & Admin Expense | 370.5M | 284.3M | 215.3M | 173.6M | 178.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 342.0K | — | (339.4M) | (330.1M) | (240.8M) |
| Total Operating Expenses | 764.9M | 690.2M | 215.3M | 173.6M | 178.0M |
| Cost and Expenses | 775.6M | 700.3M | 554.7M | 503.7M | 418.8M |
| Operating Income (EBIT) | (704.6M) | (612.3M) | (536.2M) | (496.2M) | (324.2M) |
| Non-Operating | |||||
| Interest Income | 46.7M | 48.4M | 51.5M | 27.6M | 11.3M |
| Interest Expense | 124.8M | 103.9M | 86.5M | 57.7M | 51.2M |
| Net Interest Income | (78.1M) | (55.4M) | (35.0M) | (30.0M) | (39.8M) |
| Other Non-Op Income/Expense | (189.4M) | (172.7M) | (53.3M) | (30.0M) | (64.8M) |
| Non-Operating Income (excl Interest) | 129.7M | 172.7M | (33.2M) | (27.6M) | 13.6M |
| EBT (Pre-Tax Income) | (894.0M) | (785.0M) | (589.5M) | (526.2M) | (389.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (894.0M) | (785.0M) | (589.5M) | (526.2M) | (389.0M) |
| Earnings from Cont. Ops | (894.0M) | (785.0M) | (589.5M) | (526.2M) | (389.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (894.0M) | (785.0M) | (589.5M) | (526.2M) | (389.0M) |
| Per Share | |||||
| Basic EPS | ($7.21) | ($6.54) | ($5.26) | ($5.45) | ($4.33) |
| Diluted EPS | ($7.22) | ($6.54) | ($5.26) | ($5.45) | ($4.33) |
| Revenue Per Share | $0.54 | $0.73 | $0.16 | $0.08 | $1.05 |
| Shares | |||||
| Basic Shares Outstanding | 132.1M | 120.0M | 112.0M | 96.5M | 89.8M |
| Diluted Shares Outstanding | 132.1M | 120.1M | 112.0M | 96.5M | 89.8M |
| Profitability Metrics | |||||
| EBITDA | (818.6M) | (775.3M) | (493.5M) | (456.7M) | (329.4M) |
| D&A | 15.7M | 9.7M | 9.5M | 11.9M | 8.4M |
| EBIT | (834.3M) | (785.0M) | (503.0M) | (468.6M) | (337.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026